Here are seven biopharma-related trends for 2026 that have emerged from GEN interviews with experts and other industry stakeholders, and from reviews of reports and public statements.

Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

RXRX Stock jumps after JPMorgan upgrade and trial data boost, fueling investor optimism in Recursion’s AI drug discovery ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven ...

AgentLISA, the leading Agentic Security Operating System for Web3, today announced PaymentShield, a comprehensive ...

Toward the end of this decade, a choice may face the species that could reshape its interactions with intelligence itself and ...

Precise underwater navigation is critical for autonomous and remotely operated deep-sea vehicles, yet variations in seawater ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and ...

Amazon Q Developer is a useful AI-powered coding assistant with chat, CLI, Model Context Protocol and agent support, and AWS ...

Baystreet.ca News Commentary – Artificial intelligence and platform-based approaches reshaped cancer treatment development in ...

November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies ...

November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches([1]) . The global anticancer drug market now values ...